{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:26:26Z","timestamp":1786983986649,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007914","name":"University of Texas Southwestern Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["academicradiology.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.acra.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T01:15:40Z","timestamp":1478222140000},"page":"111-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT"],"prefix":"10.1016","volume":"24","author":[{"given":"Jason W.","family":"Wachsmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramapriya","family":"Ganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acra.2016.08.005_bib0010","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.hoc.2014.02.004","article-title":"Melanoma adjuvant therapy","volume":"28","author":"Tarhini","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.acra.2016.08.005_bib0015","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1097\/01.DSS.0000452626.09513.55","article-title":"Current systemic therapies for melanoma","volume":"40","author":"Palathinkal","year":"2014","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.acra.2016.08.005_bib0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","article-title":"Systematic review of medical treatment in melanoma: current status and future prospects","volume":"16","author":"Garbe","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.acra.2016.08.005_bib0025","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from Phase II and Phase III trials of Ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acra.2016.08.005_bib0030","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/era.09.25","article-title":"Current systemic therapy for metastatic melanoma","volume":"9","author":"Agarwala","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.acra.2016.08.005_bib0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/CJI.0b013e3182742c27","article-title":"Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2","volume":"35","author":"Joseph","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.acra.2016.08.005_bib0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acra.2016.08.005_bib0045","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00259-011-1749-5","article-title":"18F-FDG PET\/CT imaging of an anti-CTLA-4 antibody-associated autoimmune pancolitis","volume":"38","author":"Goethals","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.acra.2016.08.005_bib0050","author":"BMS"},{"key":"10.1016\/j.acra.2016.08.005_bib0055","first-page":"857519","article-title":"Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica (Cairo)"},{"key":"10.1016\/j.acra.2016.08.005_bib0060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CMR.0000000000000158","article-title":"The cost of ipilimumab toxicity: a single-centre analysis","volume":"25","author":"Yousaf","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.acra.2016.08.005_bib0065","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.acra.2016.08.005_bib0070","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2478\/pjs-2014-0017","article-title":"Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab\u2014case report","volume":"86","author":"Dilling","year":"2014","journal-title":"Pol Przegl Chir"},{"key":"10.1016\/j.acra.2016.08.005_bib0075","doi-asserted-by":"crossref","first-page":"W468","DOI":"10.2214\/AJR.12.9751","article-title":"Ipilimumab-associated colitis: CT findings","volume":"200","author":"Kim","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.acra.2016.08.005_bib0080","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/RLU.0b013e3182a77cae","article-title":"Comparison of whole-body versus limited whole-body 18F-FDG PET\/CT scan in malignant cutaneous melanoma","volume":"38","author":"Lazaga","year":"2013","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.acra.2016.08.005_bib0085","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/RLU.0000000000000788","article-title":"Detection of widespread metastasis in a case of aggressive carcinoma showing thymus like differentiation (CASTLE Disease) using 18F-FDG PET\/CT","volume":"40","author":"Iyamu","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.acra.2016.08.005_bib0090","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/01.rlu.0000222954.38724.be","article-title":"Use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: report of a retrospective case study","volume":"31","author":"Peng","year":"2006","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.acra.2016.08.005_bib0095","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1536-1632(02)00014-8","volume":"4","author":"Chin","year":"2002","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.acra.2016.08.005_bib0100","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/MNM.0b013e32833f6137","article-title":"Impact of [F-18] FDG-PET\/CT in the restaging and management of patients with malignant melanoma","volume":"31","author":"Etchebehere","year":"2010","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.acra.2016.08.005_bib0105","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","article-title":"Predictive value of early 18F-FDG PET\/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study","volume":"42","author":"Sachpekidis","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.acra.2016.08.005_bib0110","doi-asserted-by":"crossref","first-page":"20140324","DOI":"10.1259\/bjr.20140324","article-title":"Non-cutaneous melanoma: is there a role for (18)F-FDG PET-CT?","volume":"87","author":"Murphy","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.acra.2016.08.005_bib0115","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1097\/RLU.0b013e3182639765","article-title":"Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab","volume":"38","author":"van der Hiel","year":"2013","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.acra.2016.08.005_bib0120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/RLU.0b013e318248549a","article-title":"Ipilimumab-induced colitis on FDG PET\/CT","volume":"37","author":"Lyall","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.acra.2016.08.005_bib0125","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/RLU.0000000000000606","article-title":"Ipilimumab-induced hepatitis on 18F-FDG PET\/CT in a patient with malignant melanoma","volume":"40","author":"Raad","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.acra.2016.08.005_bib0130","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT","volume":"40","author":"Bacanovic","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.acra.2016.08.005_bib0135","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/RLU.0b013e31828da691","article-title":"Ipilimumab-induced immunomediated adverse events: possible pitfalls in (18)F-FDG PET\/CT interpretation","volume":"39","author":"Gilardi","year":"2014","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.acra.2016.08.005_bib0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clineuro.2014.06.011","article-title":"Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis","volume":"125","author":"Chodakiewitz","year":"2014","journal-title":"Clin Neurol Neurosurg"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633216301805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633216301805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T10:49:30Z","timestamp":1616842170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633216301805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1076633216301805"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2016.08.005","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}